A clinical trial testing Esperion Therapeutics’ Bempedoic acid with the actives in Merck’s Zetia and Pfizer’s Lipitor has concluded with successful results. Patients taking part in the study reported an average of 64% decrease in LDL cholesterol. These results have proven to be more promising for cholesterol lowering than a combination of Zetia and Lipitor on their own. The results of a phase 3 trial will be published in the first quarter of 2018 along with plans for further combination studies. Read the full press release here.